X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.
Lead Product(s): Olanzapine
Therapeutic Area: Psychiatry/Psychology Product Name: TEV-‘749
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Teva Pharmaceutical Industries
Deal Size: $125.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration November 13, 2023
Details:
Under the agreement, Royalty Pharma acquires additional royalties on Evrysdi (risdiplam), a survival motor neuron 2 splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to survival motor neuron protein deficiency.
Lead Product(s): Risdiplam
Therapeutic Area: Genetic Disease Product Name: Evrysdi
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: PTC Therapeutics
Deal Size: $1,500.0 million Upfront Cash: $1,000.0 million
Deal Type: Agreement October 19, 2023
Details:
The proceeds will support continued development and commercialization of Endocrine Rare Disease products, including SKYTROFA (lonapegsomatropin-tcgd), a prodrug of somatropin, administered once weekly, and designed to provide sustained release of active, unmodified somatropin.
Lead Product(s): lonapegsomatropin-tcgd
Therapeutic Area: Endocrinology Product Name: Skytrofa
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Ascendis Pharma
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 05, 2023
Details:
Under the agreement, Royalty Pharma is acquiring a 5.1 percentage royalty on net sales of Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy developed as a treatment for adult patients with BCG-unresponsive NMIBC, in the United States.
Lead Product(s): Nadofaragene Firadenovec-vncg
Therapeutic Area: Oncology Product Name: Adstiladrin
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Recipient: Ferring Pharmaceuticals
Deal Size: $500.0 million Upfront Cash: $300.0 million
Deal Type: Agreement August 23, 2023
Details:
Under the agreement, Royalty Pharma will acquire PureTech’s royalty in Karuna’s KarXT (xanomeline), an oral, investigational M1/M4-preferring muscarinic agonist for the treatment of psychiatric and neurological conditions, including schizophrenia and psychosis in Alzheimer.
Lead Product(s): Xanomeline,Trospium Chloride
Therapeutic Area: Psychiatry/Psychology Product Name: KarXT
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Karuna Therapeutics
Deal Size: $500.0 million Upfront Cash: $100.0 million
Deal Type: Agreement March 23, 2023
Details:
Pfizer has given Royalty Pharma an accelerated milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant). Zavzpret was approved by the U.S. FDA, which provides another important new treatment option for migraine patients.
Lead Product(s): Zavegepant
Therapeutic Area: Neurology Product Name: Zavzpret
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $475.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 15, 2023
Details:
Spinraza (nusinersen) is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
Lead Product(s): Nusinersen
Therapeutic Area: Genetic Disease Product Name: Spinraza
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Ionis Pharmaceuticals
Deal Size: $1,125.0 million Upfront Cash: $500.0 million
Deal Type: Agreement January 09, 2023
Details:
AMG 890 (olpasiran) is a siRNA originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM™, platform. It is designed to lower levels of lipoprotein(a) (Lp(a)), a genetically-determined independent risk factor for cardiovascular disease.
Lead Product(s): Olpasiran
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 890
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Arrowhead Pharmaceuticals
Deal Size: $410.0 million Upfront Cash: $250.0 million
Deal Type: Licensing Agreement November 09, 2022
Details:
The Company now anticipates it will approach breakeven cash flow in the second half of 2022 without the cash flows from its interest in GSK's Trelegy Ellipta (fluticasone furoate) royalties, driven by disciplined spending within R&D and the growth of YUPELRI®.
Lead Product(s): Fluticasone Furoate,Umeclidinium Bromide,Vilanterol Trifenatate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Trelegy Ellipta
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Theravance Biopharma
Deal Size: $1,550.0 million Upfront Cash: $1,100.0 million
Deal Type: Divestment July 13, 2022
Details:
GAVRETO is an important precision therapy that has been incredibly meaningful for patients with metastatic, RET fusion-positive non-small cell lung cancer who may have otherwise had limited options.
Lead Product(s): Pralsetinib
Therapeutic Area: Oncology Product Name: Gavreto
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Blueprint Medicines
Deal Size: $340.0 million Upfront Cash: $175.0 million
Deal Type: Collaboration June 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
